Among patients with familial amyloid polyneuropathy (FAP), those with transthyretinVal30Met mainly show distally predominant weakness and atrophy, whereas some FAP patients, including those with transthyretinSer50Ile and Tyr114Cys, show muscle weakness and atrophy that is dominant proximally, simulating myopathy.